Journals / Turkish Neurosurgery / 2020 / Cilt: 30 - Sayı: 6

Retrospective Analysis of Survival in Patients with Brain Metastases from an Unknown Primary Tumor

Pages
932–936
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, BMUP cancer is indeed related to poor prognosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: To evaluate the patients with brain metastases from unknown primary (BMUP) cancers, and to analyze the prognostic factors and survival rates.
📊
Key Findings & Data:MATERIAL and METHODS: We conducted a retrospective study with 110 patients (mean age: 62.8 years [range 23–90], n=85-77.3% male and n=25-22.7% female) with BMUP cancers at the time of diagnosis, who presented to our outpatient oncology clinic between January 2015 and December 2019.
💡
Conclusion & Impact:Therefore, BMUP cancer is indeed related to poor prognosis.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Özet

AIM: To evaluate the patients with brain metastases from unknown primary (BMUP) cancers, and to analyze the prognostic factors and survival rates. MATERIAL and METHODS: We conducted a retrospective study with 110 patients (mean age: 62.8 years [range 23–90], n=85-77.3% male and n=25-22.7% female) with BMUP cancers at the time of diagnosis, who presented to our outpatient oncology clinic between January 2015 and December 2019. We employed the following variables as significant prognostic factors for a prominent index of patients’ survival: age, gender, Karnofsky performance score (KPS), number of metastatic lesions, primary site, and type of treatment were analyzed for their prognostic effects on survival outcomes. Patients’ survival was evaluated from plotted Kaplan–Meier curves, and the log-rank test was used for univariate analysis.RESULTS: The mean follow-up was 13 months (range 4–60 months). The means of survival after the diagnosis of brain metastasis was 18.7 months for the study group. Lung cancer was the most common primary tumor (74, 5%). The KPS and number of lesions were found to have a prognostic effect on survival. Survival analysis showed no statistical significance with age and gender, primary site, type of treatment.CONCLUSION: This study showed that KPS, and the number of lesions affect the survival outcomes but both the other variables. Therefore, BMUP cancer is indeed related to poor prognosis.

🔖

Cite This Article

ÇIRAK, M., GUCLU, D. G., AKAR, E., KAZANCI, M. H., TURAL, D. (2020). Retrospective Analysis of Survival in Patients with Brain Metastases from an Unknown Primary Tumor. Turkish Neurosurgery, Cilt: 30 - Sayı: 6, 932–936. https://ajindex.com/articles/404305

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Bartelt S, Lutterbach J: Brain metastases in patients with cancer of unknown primary. J Neurooncol 64:249-253, 2003 2. Bertolini F, Spallanzani A, Fontana A, Depenni R, Luppi G: Brain metastases: An overview. CNS Oncol 4:37-46, 2015 3. D’Ambrosio AL, Agazzi S: Prognosis in patients presenting with brain metastasis from an undiagnosed primary tumor. Neurosurg Focus 22(3):E7, 2007 4. Deshpande K, Buchanan I, Martirosian V, Neman J: Clinical perspectives in brain metastasis. Cold Spring Harb Perspect Med 10(6):a037051, 2020 5. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751,1997 6. Gough M, Nielsen M, Coulter IC, Holliman D: Survival outcomes following craniotomy for intracranial metastases from an unknown primary. Int J Clin Oncol 25(8):1475-1482, 2020 7. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI: Identification of prognostic factors in patients with brain metastases: A review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795-803, 1999 8. Nieder C, Spanne O, Mehta MP, Grosu AL, Geinitz H: Presentation, patterns of care, and survival in patients with brain metastases: What has changed in the last 20 years? Cancer 117:2505-2512, 2011 9. Nolan C, Deangelis LM: Overview of metastatic disease of the central nervous system. Handb Clin Neurol 149:3-23, 2018 10. Nussbaum ES, Djalilian HR, Cho KH, Hall WA: Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78:1781-1788, 1996 11. Rotta JM, Rodrigues DB, Diniz JM, Abreu BM, Kamimura F, Sousa UO, Botelho RV, Oliveira MF: Analysis of survival in patients with brain metastases treated surgically: Impact of age, gender, oncologic status, chemotherapy, radiotherapy, number and localization of lesions, and primary cancer site. Rev Assoc Med Bras 64:717-722, 2018 12. Smedby KE, Brandt L, Bäcklund ML, Blomqvist P: Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 101:1919-1924, 2009 13. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W: A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:510-514, 2008